Compare · ORKA vs VNRX
ORKA vs VNRX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 1284.2x VNRX ($5.2M).
- ORKA has been more active in the news (11 items in the past 4 weeks vs 9 for VNRX).
- ORKA has more recent analyst coverage (11 ratings vs 4 for VNRX).
- Company
- Oruka Therapeutics Inc.
- VolitionRX Limited
- Price
- $101.87-0.53%
- $0.38-2.10%
- Market cap
- $6.74B
- $5.2M
- 1M return
- -
- -56.47%
- 1Y return
- -
- -97.15%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 11
- 9
- Recent ratings
- 11
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Latest VNRX
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form S-8 filed by VolitionRX Limited
- SEC Form 10-Q filed by VolitionRX Limited
- VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
- Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
- VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
- Volition Advances Nu.Q® NETs Platform Towards Commercialization